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Abstract.  The secreted polypeptide transforming 
growth factor-/3 (TGF-fl) exerts its multiple activities 
through type I and II cell surface receptors. In epithe- 
lial cells, activation of the TGF-fl signal transduction 
pathways leads to inhibition of cell proliferation and 
an increase in extracellular matrix production. TGF-/3 
is widely expressed during development and its biolog- 
ical activity has been implicated in epithelial-mesen- 
chymal interactions, e.g., in branching morphogenesis 
of the lung, kidney, and mammary gland, and in in- 
ductive events between mammary epithelium and 
stroma. 
In the present study, we investigated the effects of 
TGF-/3 on mouse mammary epithelial cells in vitro. 
TGF-/3 reversibly induced an alteration in the differen- 
tiation of normal mammary epithelial NMuMG cells 
from epithelial to fibroblastic phenotype. The change 
in cell morphology correlated with (a) decreased ex- 
pression of the epithelial markers E-cadherin, ZO-1, 
and desmoplakin I and II; (b)  increased expression of 
mesenchymal markers, such as fibronectin; and (c) a 
fibroblast-like reorganization of actin fibers.  This 
phenotypic differentiation displays the hallmarks 
of an epithelial to mesenchymal transdifferentiation 
event. 
Since NMuMG cells make high levels of the type I 
TGF-fl receptor Tsk7L, yet lack expression of the 
ALK-5/R4 type I receptor which has been reported to 
mediate TGF-/~ responsiveness, we evaluated the role 
of the Tsk7L receptor in TGF-~-mediated transdiffer- 
entiation. We generated NMuMG cells that stably over- 
express a truncated Tsk7L type I receptor that lacks 
most of the cytoplasmic kinase domain, thus function 
as a dominant negative mutant. These transfected cells 
no longer underwent epithelial to mesenchymal mor- 
phological change upon exposure to TGF-fl,  yet still 
displayed some TGF-fl-mediated responses. 
We conclude that TGF-fl has the ability to modulate 
E-cadherin expression and induce a reversible epithe- 
lial to mesenchymal transdifferentiation in epithelial 
cells. Unlike other transdifferentiating growth factors, 
such as bFGF and HGF, these changes are accompa- 
nied by growth inhibition. Our results also implicate 
the Tsk7L type I receptor as mediating the TGF-~- 
induced epithelial to mesenchymal transition. 
T 
RANSFORMING growth factor-# fIGF-~)' is a secreted 
growth and differentiation factor that exists as three 
different isoforms, and exerts a variety of biological 
activities  depending  on the target cell type (Roberts  and 
Sporn,  1991; Derynck, 1994a). Following interaction  with 
its cell surface receptors,  TGF-/3 has the ability to stimulate 
or inhibit cell proliferation.  The antiproliferative activity is 
best documented in  epithelial  cells,  whereas the growth 
stimulatory effect occurs mainly in cells of mesenchymal  ori- 
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gin such as fibroblasts. TGF-/3 also increases the expression 
of several extraceUular matrix proteins  and integrin recep- 
tors for extracelhlar matrix components,  and inhibits the 
proteolytic degradation of this matrix (Edwards et al., 1987; 
Roberts et al., 1988; Heino et al., 1989; Ignotz et al., 1989). 
TGF-/3 furthermore affects cell differentiation, which may be 
related to its ability to modulate cell interaction with the ex- 
traceUular  matrix.  Among mesenchymal cells,  TGF-/3 is 
known to inhibit adipocyte differentiation,  stimulate chon- 
drocyte formation and inhibit or stimulate myoblast and os- 
teoblast differentiation depending on the physiological con- 
ditions and stage of differentiation of the specific cell type 
(Roberts and Sporn,  1991; Derynck, 1994a). Many mem- 
bers of  the large TGF-fl superfamily, including the bone mor- 
phogenetic  factors  (BMPs) and the activins,  also  strongly 
affect mesenchymal differentiation pathways, thus making it 
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cell types may be  orchestrated by the interplay of TGF- 
fl-related factors (Kingsley,  1994). 
During development, TGF-B expression is often detected 
in  both  epithelial  and  mesenchymal cells  (Heine  et  al., 
1987).  Most notably, TGF-fl is frequently localized at sites 
of interaction between the epithelium and mesenchyme, sug- 
gesting a  functional involvement for TGF-fl in epithelial- 
mesenchymal interactions. In this context, TGF-fl may spe- 
cifically modulate the branching morphogenesis of several 
organs such as the lung, kidney, and mammary gland (Silber- 
stein and Daniel, 1987; Heine et al., 1990; Robinson et al., 
1991; Rogers et al., 1993). All three TGF-fl isoforms are ex- 
pressed in the developing mouse mammary gland (Robinson 
et al., 1991). Their expression patterns are somewhat over- 
lapping, since each isoform is produced by both mammary 
epithelial and stromal cells. Exogenous TGF-fl inhibits both 
formation and growth of ductal buds and stimulates produc- 
tion of extracellular matrix (Silberstein and Daniel,  1987; 
Daniel et al., 1989; Silberstein et al., 1990; Robinson et al., 
1991).  Moreover,  overexpression of active TGF-fll in the 
mammary gland of transgenic mice results in the formation 
ofa hypoplastic ductal tree (Pierce et al., 1993). This further 
suggests a role for TGF-fl as a regulator of ductal growth. 
How TGF-fl exerts its variety of activities at the receptor 
level is at present largely unknown. Chemical cross-linking 
of radiolabeled TGF-B to cell surface TGF-fl-binding pro- 
teins has revealed the existence of  up to nine different "recep- 
tors" (Massagut,  1992).  Among these, the types I, II, and 
HI TGF-/~ receptors are most frequently detected in the sur- 
face of many different cell types. The type III receptor, also 
called betaglycan, is a cell surface proteoglycan that presum- 
ably does not have any signaling activity (Lopez-Casillas et 
al., 1991; Wang et al., 1991). However, it may enhance pre- 
sentation of TGF-# to the type II receptor (Lopez-Casillas 
et al.,  1993; Moustakas et al.,  1993).  In contrast, the type 
II and type I receptors mediate most, if not all TGF-/3 signal- 
ing (Laiho et al.,  1990).  Molecular cloning and character- 
ization of the in vitro kinase activity has shown that both 
receptor types are transmembrane serine/threonine kinases. 
Only one type II TGF-B receptor has been cloned and shown 
to bind TGF-B without the requirement of another receptor 
or detectable accessory protein (Lin et al.,  1992).  In con- 
trast, cDNAs for several type I receptors have been charac- 
terized,  including Tsk7L  (Ebner  et  al.,  1993a),  ALK-5/ 
R-4/ESK-2 (Franztn et al., 1993;  He et al.,  1993; Bassing 
et al., 1994a;  Tomoda et al., 1994), and TSR-1 (Attisano et 
al., 1993) receptors. The ability of these type I receptors to 
bind  TGF-/3 depends  on the  coexpression of the  type II 
TGF-fl receptor (Ebner et al., 1993a; Bassing et al., 1994b). 
The type II receptor can physically interact with the type I 
receptor,  and in this way provides ligand  specificity and 
affinity (Wrana et al., 1992; Ebner et al., 1993b;  ten Dijke 
et al., 1994). Thus, in the presence of activin type II recep- 
tor, the Tsk7L type I receptor binds activin and, in the pres- 
ence of TGF-fl type II receptors, it binds TGF-B (Ebner et 
al.,  1993b).  The relative contributions of the type I and II 
receptors to the multiple activities of TGF-/3 remain unclear. 
We have previously proposed that in epithelial cells, the type 
II receptor, presumably in combination with the type I recep- 
tor, mediates the antiproliferative effect of TGF-fl, and that 
the TGF-fl-induced increase in fibronectin and PAI-1 synthe- 
sis as well as c-jun expression is mediated through the type 
I receptor (Chen et al., 1993). However, Wieser et al. (1993) 
have reported that the transcriptional and antiproliferative 
responses to TGF-fl require fully functional forms of both 
type I and II receptors. Whereas several type I receptors bind 
TGF-fl when coexpressed with the type II TGF-B receptor 
(ten Dijke et al., 1994),  only one of these, namely ALK-5/ 
R-4, has been shown to restore TGF-/~ responsiveness in a 
mutant mink lung epithelial cell line lacking type I receptors 
(Bassing et al.,  1994a;  Carc~imo et al.,  1994;  ten Dijke et 
al.,  1994).  No TGF-fl mediated functional responsiveness 
has as yet been documented for the type I receptor Tsk7L 
(Ebner et al.,  1993a). 
In the present study, we have investigated the effect of 
TGF-fl on mouse mammary epithelial cells in vitro. TGF-B 
inhibited proliferation of these cells and concomitantly in- 
duced an epithelial to fibroblastic transdifferentiation. This 
reversible morphological transdifferentiation was accompa- 
nied by changes in expression patterns for specific epithelial 
markers such as E-cadherin, and suggests a role for TGF-/~ 
as a differentiation factor e.g. at sites of epithelial to mesen- 
chymal transitions. Since the NMuMG epithelial cells lack 
ALK-5/R-4 type I receptors for "I'GF-B  but express high lev- 
els of Tsk7L type I receptors, we used this TGF-fl dependent 
transdifferentiation to evaluate the-involvement of Tsk7L in 
TGF-fl-induced signal transduction. Inhibition of the func- 
tional expression of Tsk7L receptors by overexpressing a 
dominant negative TskTL truncated receptor resulted in inhi- 
bition of the TGF-/3-induced phenotypic differentiation sug- 
gesting,  that Tsk7L is  involved in  the transdifferentiation 
process. 
Materials and Methods 
Cell Lines and Culture Conditions 
Mouse mammary gland epithelial cells, NMuMG (CRL  1636; American 
"Dype Culture Collection [ATCC],  Rockville, MD), were obtained from Dr. 
M. Bernfield (Harvard Medical School, Boston, MA) and grown in H-21 
DMEM (4.5  g glucose/I) supplemented with 7.5%  fetal calf serum,  10 
ftg/rnl insulin, 100 #g/rnl penicillin, and 100 U/ml streptomycin. Mink lung 
(MvlLu) epithelial cells (CCL 64; ATCC)  and MDCK kidney epithelial- 
like cells (CCL 34; ATCC) were cultured in H-16 DMEM (3.0 g glucose/I) 
supplemented in  10%  fetal calf serum,  whereas COMMA-ID cells (ob- 
tained from Dr. M. Bissell, Lawrence-Berkeley Labs., Berkeley, CA) were 
grown in DME/F-12 with 5% fetal calf serum and 5 t~g/ml insulin, All cell 
lines were grown at 37°C in 5% CO2 and passaged every third day follow- 
ing 0.05 % trypsin-versene treatment. Treatments with TGF-fll (or TGF-ff2 
or activin) were initiated on day 2. 
For trypan blue staining, cells grown with or without TGF-~ were tryp- 
sinized and combined with their medium to include the detached dead cells. 
They were then spun down and mixed with an equal volume of 0.4% trypan 
blue. The proportion of  viable cells (nonstained) was determined in a count- 
ing chamber. To visualize apoptotic cells, cells were grown on coverslips 
and subsequently fixed in 70% ethanol, treated with RNaseA and stained 
with propidium iodide (Sigma Chem. Co., St. Louis, MO). 
Experiments with antisense and  sense strand oligonucleotides to the 
mouse Tsk7L type I and the mouse type H TGF-B receptor were performed 
in serum-free media supplemented with ITS (GIBCO BRL, Galthersburg, 
MD). The oligonucleotide sequences were: Tsk7L antisense 5'-TACTCC- 
ATCGACCATTGTATA-3' and sense 5'-TATACAA'IGG'I'~GA~GTA-3'; 
mouse type II receptor antisense 5'-CAGCCCCCGACCCA~AGC-3' 
and sense Y-GCTGCCATGGGTCGGC~,JC~TG-3'.  All sequences span the 
ATG start codon. The oligonucleotides (10 p.M) were added to NMuMG 
cell cultures daily staring from day  1.  TGF-B treatments were started on 
day 2. 
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Recombinant TGF-~I, TGF-~2, and activin were obtained from Genentech 
(South San Francisco, CA) and used at 2-20 ng/mi. Protein kinase C in- 
hibitors 1-I7 (final concentration 50/~M; LC Chemicals, Woburn, MA), 
HA1004 (final concentration 50 ~tM; LC Chemicals), bisindolylmaleimide 
(final concentration 1-100/~M; LC Chemicals), calphostin C (final concen- 
tration 0.5 ~tM; LC Chemicals), chelerytrine (final concentration 5 #M; 
Calbiochem-Novabiochem,  La Jolla, CA), and stanrosporine (final concen- 
tration 20 nM; Sigma Chem. Co.) were added either 5 rain before or after 
TGF-~I  stimulations.  12-o-tetradecanoyl-phorbol  13-acetate  (TPA,  final 
concentration 1-1000 ng/mi; Sigma Chem. Co.) was included in the media 
for 2 or 24 h before TGF-~ treatment. 
Cell Proliferation Assay 
NMuMG  cells  were  grown at a  density  of 5  x  lif  t  cells/well  (50% 
confluency)  in 24-well  plates.  After 24 h, the medium was  changed to 
serum-free medium and TGF-fll (2 ng/ml) was added to the medium. After 
21-h treatment, cells were incubated with 2 ILCi of methyl-3H-thymidine 
(NEN-DuPont, Boston, MA) for an additional 3 h. Ceils were then washed 
twice with ice-cold  PBS,  precipitated in  10%  trichloroacetic acid,  and 
counted for radioactivity.  Experiments were done  in triplicate and the 
results are represented as the mean value. 
Immunohistochemistry  and Western Blot Analysis 
The following antibodies were used: mouse anti-desmoplakins 1 and 2, (69- 
542; ICN Biomedicals,  Inc., Costa Mesa, CA), mouse anti-vimentin  (5255; 
Sigma);  rat  anti-E-cadherin  (U-3254;  Sigma);  rabbit  anti-fibronectin 
(F-3648; Sigma); mouse anti-vinculin (9131; Sigma); rat anti-ZO-1 (MAB 
1520; Chemicon Intl.  Inc., Temecula,  CA);  mouse anti-cytokeratin 18, a 
gift from Professor I. Virtanen (University of Helsinki).  Cells were grown 
on glass coverslips and stimulated with TGF-/31 for 24-48 h. They were then 
fixed  either in ice-cold  acetone-methanol for  10 min (mouse  anti-des- 
moplakins  1 and 2,  mouse anti-vimentin) or 3%  paraformaldehyde  for 
30 rain (rat anti-E-cadherin, rabbit anti-fibronectin,  mouse anti-vinculin, 
rat anti-ZO-1) before application of primary antibodies.  Bound antibodies 
were detected using fluorochrome-conjugated  secondary antibodies (FITC- 
or TRITC-conjngated  donkey anti-mouse-IgM, donkey anti-rat, goat anti- 
rabbit, goat anti-mouse from Jackson Biochemicals,  West Grove, PA) and 
analyzed  by fluorescence  microscopy.  Actin was  detected using FITC- 
conjugated phalloidin (from Dr. T. Mitchison, University of California, San 
Francisco) after fixation in 3 % paraformaldehyde  and permeabilization in 
0.5%  Triton X-100. 
For Western analysis, ceils cultured with or without TGF-fll were lysed 
in 2 % SDS, 50 mM Tris, pH 7.4, 2 mM EDTA with 5/~g/ml aprotinin, 5 
/zg/ml leupeptin, and 1 mM PMSE Equal protein amounts were denatured 
in reducing Laemmli sample buffer, run in 7.5% SDS-polyacrylamide gel 
at 175V (Laemmli, 1970), and electroblotted to nitrocellulose  filters (Tow- 
bin et al., 1979). Nonspecific binding to the filter was blocked by incubating 
the membranes overnight in 3% bovine serum albumin and 0.1% Tween 20 
in Tris-buffered  saline.  The membrane-bound antibodies to E-cadherin, 
fibronectin, vimentin, vinculin, and ZO-1 were visualized with alkaline- 
conjugated secondary  antibodies (Jackson)  and nitroblue tetrazolium sub- 
strate (Kilkegaard-Poulsen,  Gaithersburg, MD). For E-cadherin immuno- 
blotting analysis, the cell lysates were also incubated with concanavalin-A 
and the concanavalin-A bound fraction was used for Western blot. 
Northern Hybridization 
RNA was  extracted  from confluent  10-cm  plates of untreated or TGF- 
B-treated NMuMG ceils using Ultraspec according to the manufacturer's 
instructions (Biotecx Laboratories Inc., Houston, Texas). 30-~g RNA sam- 
ples were electrophoretically  separated on a 1.3 % agarose-formaldehyde gel 
and transferred to Hybond-N+ (Amersham Corp., Arlington Heights,  IL) 
according to standard procedures (Maniatis et al., 1982). After transfer, the 
filters were stained with 0.04 % methylene blue to confirm equal loading and 
integrity  of the RNA  samples.  Hybridization probes were  prepared by 
radiolabeling the cDNAs using the random priming method. Northern anal- 
yses were done using cDNAs for E-cadherin (gift from Dr.  M. Takeichi, 
Kyoto University,  Japan), fibronectin (Schwarzbauer  et al.,  1983), Tsk7L 
type I receptor (Ebner et ai., 1993a), and ALK-5/R4 type I receptor (a PCR 
fragment containing the cytoplasmic  kinase domain). Filters were hybrid- 
ized overnight at 420C with 1 ×  106 cpm/ml of each cDNA probe in hy- 
bridization buffer  (50%  formamide,  0.5%  SDS,  5x  Denhardt's solution, 
0.15 mg/ml salmon sperm DNA, washed in 0.Ix  SSC, 0.1% SDS at 52°C 
for 1 h and exposed  for autoradiography.  To detect mRNA for the ALK- 
5/R4 type I receptor,  we used low-stringency washes, i.e., 0.5x SSC, 0.1% 
SDS at 42°C for  1 h. 
Generation of Stable Transfected Cell Clones 
The expression plasmid for the cytoplasmically  truncated form of the Tsk7L 
(TskTL-DN) with a COOH-terminal Flag epitope tag has been described 
previously  (Ebner,  1993a).  This truncated form has Glu  155 as  the last 
amino acid of the receptor thus lacking  the GS  domain  (amino acids 
191-195), which is conserved among type I receptors.  NMuMG cells were 
transfected with Tsk7L-DN together with an expression plasmid containing 
the neomycin resistance gene using Lipofectamine  following the manufac- 
turer's instructions (GIBCO BRL,  Grand Island, NY).  Transfected  cell 
clones surviving neomycin selection (G418 700/zg/ml, GIBCO BRL) were 
screened  by nonradioactive  Northern blot analysis  (Engler-Blum  et al., 
1993) with some modifications.  First, RNA isolated using Ultraspec (Bio- 
tecx) was separated in 1.3 % agarose formaldehyde gel and capillary blotted 
onto Hybond-N+  membrane (Maniatis et al.,  1982).  Full-length Tsk7L 
cDNA probe was  random prime labeled with digoxigenin-dCTP  (Boeh- 
ringer Mannheim, Indianapolis,  IN) according to manufacturer's  instruc- 
tions.  Northern blots were prehybridized  in 20% SDS, 0.25 M Na2HPO4 
(pH 7.2),  1 mM EDTA, 0.5%  blocking buffer (Boehringer Mannheim) at 
68°C for 1 h and with 2.5 ng/ml of labeled probe for additional 14-18 h. 
The blots were next washed in 0.1% SDS, 0.1x SSC at 68°C for 3 x  20 rain. 
The bound probe was detected with alkaline-phosphatase-conjngated  anti- 
digoxigenin  antibody and Lumiphos-created  chemiluminescence (Boeh- 
ringer Mannheim). 
Biotinylation of Cell Surface Proteins 
and Immunoprecipitation 
Cell surface proteins including the TGF-fl receptors were biotinylated  as de- 
scribed (Lopoz-Casillas  et al.,  1993).  Briefly, near-confluent  cells (wild- 
type NMuMG, TsldL-DN clones, or NMuMG transiently transfected  with 
Tsk7L-DN)  were  washed  with  Krebs-Ringer  buffer  containing 20  mM 
Hepes,  pH 7.2.  Sulfosuccinimidyl  6-(biotinamido)  hexanoate  (NHS-LC- 
biotin; Pierce Chemical, Rockford,  IL) was then added to the cells at 1 
mg/ml in Krebs-Ringer  buffer and incubated 2 h at 4°C. The biotinylation 
reaction was quenched by adding 10 mM glycine, 0.4 M sucrose,  10 mM 
Tris-HC1  (pH  7.4),  1.5 mM CaCI2, 5 mM MgCI2. The cells were then 
scraped into lysis buffer (25 mM Tris-HCl, pH 7.5, 0.3 M NaCI, 0.5% Tri- 
ton X-100, 0.5 mM EGTA, 0.1% BSA, 5 #g/ml aprotinin, 5 t~g/ml leupeptin, 
and I mM PMSF) and subjected to immunoprecipitation with anti-Flag M2 
antibody  (4 t~g/ml; IBI,  Eastman Kodak,  New Haven).  After addition of 
rabbit anti-mouse IgG  bound to  Protein-A  (Pharmacia LKB  Nuclear, 
Gaithersburg,  MD), the immunoprecipitates were  washed  twice in lysis 
buffer  without BSA  and  proteinase  inhibitors and twice  in 0.25  mM 
Tris-HCl (pH 7.5), 0.15 mM NaCI.  The samples  were then run in 15% 
SDS-polyacrylamide  gel under reducing conditions,  electrotransferred  to 
nitrocellulose  and incubated overnight  in 0.5%  Tween 20,  1 M  glucose, 
10%  glycerol,  3%  BSA,  1%  skimmed milk in PBS  to block nonspe- 
cific binding of streptavidin.  The biotinylated proteins were detected us- 
ing streptavidin-conjugated  peroxidase  and the ECL system  (Amersham 
Corp.). 
lzSI-TGF-~ Crosslinking 
Near-confluent  cells were washed in binding buffer (Krebs-Ringer  with 20 
mM Hepes and 0.5%  BSA) and then incubated with 50 pM lz~I-TGFq3 
(Amersham Corp.) in binding buffer for 4 h at 4"C and cross-linked  as de- 
scribed (Wang et al., 1991). Cells were then scraped in 1 ml binding buffer, 
centrifuged,  and resulting pellets were further resuspended  in 60 t~l of lysis 
buffer (10 mM Tris-HCl, pH 7.4,  1 mM EDTA, pH 8.0, 1% Triton X-100 
with 5 t~g/ml aprotinin, 5 tzg/ml leupeptin,  and 1 mM PMSF). After cen- 
trifugation,  the soluble fraction was mixed with 5 x  Laemmli sample buffer 
containing 25%  fl-mercaptoethanol  and separated on 12.5%  SDS-POly- 
acrylamide gels. After fixation in 50% methanol, 10% acetic acid, the gel 
was exposed for autoradiography.  In some experiments, wild-type NMuMG 
cells and Tsk7L-DN clones were transiently transfected with an expression 
plasmid for the mouse type II TGF-~ receptor (Lawler et al.,  1994) using 
Lipofectamine. 
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TGF-(3 Induces an Epithelial to Mesenchymal 
Differentiation  in NMuMG Cells 
TGF-~ is a known inhibitor of cell proliferation for a variety 
of cell types, including epithelial cells. NMuMG mammary 
epithelial cells were tested for their response to TGF-/~. This 
immortalized cell line,  derived from a  normal mammary 
gland is not transformed as assessed from its behavior in cell 
culture and does not form malignant tumors in vivo. Micro- 
scopic examination of the cells surprisingly revealed a dras- 
tic alteration in  cell  shape  following exposure to TGF-/3. 
Whereas the untreated NMuMG cells displayed the cuboidal 
appearance characteristic of epithelial cells, treatment with 
TGF-~I induced a phenotypic change which made the cells 
elongated and spindle-shaped,  i.e.,  characteristic of fibro- 
blasts (Fig.  1). The effect was dose dependent and was al- 
ready apparent at a concentration of  0.5 ng/ml, but was faster 
and more pronounced at higher concentrations of TGF-/~I 
(up to 10 ng/ml). However, the maximum effect was already 
reached at 2 ng/ml of TGF-/31. The phenotypic change in the 
differentiation state was evident within 16-18 h after addition 
of TGF-/3. TGF-B2 also induced the same phenotypic altera- 
tion in differentiation state. TGF-/33 was not available for our 
experiments.  However, activin A,  another member of the 
TGF-/~ superfamily,  had  no  effect on  the  morphology of 
NMuMG cells at varying concentrations (up to 20 ng/ml). 
The  differentiation  towards  fibroblast-like  phenotype  re- 
quired only a brief exposure to TGF-/3, as low as 5 min. Fi- 
nally, this effect of TGF-/$ was reversible, since removal of 
TGF-/~ from the culture media restored the epithelial pheno- 
type within 2 d. 
The proliferative response to NMuMG cells was tested in 
a  [3H]thymidine  incorporation  assay,  indicative  of DNA 
synthesis  and  cell  proliferation.  These  experiments  were 
done not only in serum-containing but also in serum-free 
medium to exclude the effects due to serum-derived TGF-/3s 
and other growth factors. The DNA synthesis of NMuMG 
cells treated with 2 ng/ml of TGF-/31 was reduced by 60% 
(Fig. 2 A) both in the presence and absence of serum. The 
proliferation of these cells as measured by counting the cell 
number was similarly decreased (Fig. 2 B) without any sign 
of increased cell death or apoptosis as analyzed by trypan 
blue and propidium iodide staining  (data not shown).  To 
evaluate whether the TGF-/~-induced epithelial to fibroblas- 
tic differentiation was restricted to NMuMG cells or was a 
more general  response  of epithelial  cells,  we  also  tested 
several other epithelial cell lines.  Several other cell lines 
tested, the lung epithelial MvlLu cells and the kidney epithe- 
Figure/. TGF-/$  induces an epithelial to mesen- 
chymal differentiation in normal mammary epi- 
thelial NMuMG cells. Untreated NMuMG cells 
exhibited a cuboidal,  epithelial cell phenotype 
(WT), while  36-h  treatment  with  TGF-/51 (2 
ng/ml) induced a fibroblastic transition resulting 
in an elongated, spindle cell morphology. 
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NMuMG  cells  after  TGF-/3 
treatment. (A) NMuMG cells 
were treated with TGF-/~I (2 
ng/ml or 10 ng/ml) for 24 h. 
Their rate of DNA synthesis 
was assayed by measuring the 
uptake  of  [SH]thymidine at 
21 h after initiation of TGF-B 
treatment.  Serum-free media 
was  used  to  exclude  effects 
due to serum-derived TGF-/3 
and other growth factors. As 
shown, "rGF-/~  was growth in- 
hibitory both in the presence 
and  absence  of  serum.., 
CO;  [],  2  ng/ml TGF-/~; [] 
10 ng/ml TGF-/L (B) NMuMG 
ceils were plated in 24-well plates at a density of 50,000 cells/well. TGF-/31 treatment (2 ng/ml) was started on the following day. Cells 
were then trypsinized and counted daily starting at 24 h after initiation of TGF-/~ treatment. The number of cells in the TGF-/3-treated 
wells was approximately half of the control wells, indicative of the antiproliferative effect of TGF-B. u, without TGF-/3; z~, with 2 ng/ml 
TGF-~. 
lial  MDCK  cells at  low density and  mammary epithelial 
COMMA-ID cells, all responded to TGF-/~ with a  similar 
change in morphology, although the cells were generally less 
spindle-shaped even at higher concentrations of TGF-/~ (data 
not shown). 
Characterization of the Alteration 
in Differentiation State 
To further characterize the shape change of the NMuMG 
cells following treatment with TGF-/3, we tested whether the 
change in morphology correlated with the disappearance of 
epithelial  markers  and  appearance  of mesenchymal  cell 
markers. As epithelial markers, we examined the expression 
of desmoplakins 1 and 2, E-cadherin, vinculin, and ZO-1 by 
immunofluorescence. To characterize the fibroblastic char- 
acter of the TGF-/%treated cells, we used immunofluores- 
cence to determine the expression of fibronectin, vimentin 
and the characteristic intracellular pattern of  actin fibers. For 
this purpose, NMuMG cells were grown on coverslips with 
or without TGF-B and stained with various antibodies to the 
above mentioned cytoskeletal proteins. 
In untreated NMuMG cells, E-cadherin was located at the 
cell surface and appeared as a continuous line at the bound- 
aries between neighboring cells, characteristic for epithelial 
cells. Following TGF-/3 treatment, this epithelial pattern dis- 
appeared  and  the  immunostaining  was  more  diffuse and 
drastically decreased or was absent in the fibroblastic cells 
(Fig.  3, A  and B).  Without TGF-/~ treatment,  the immu- 
noreactivity pattern for ZO-1,  a tight junction protein, was 
very similar  to  the  epithelial  E-cadherin  immunofluores- 
cence staining. As in other epithelial cells, the ZO-1 protein 
was localized as a continuous line at the cell-cell boundaries. 
However, upon  TGF-/31 treatment,  the  ZO-1  staining  de- 
creased and displayed a somewhat coarser, punctate-like pat- 
tern at the cell boundaries (Fig. 3, C and D). Also, the stain- 
ing patterns for desmoplakins,  vinculin (Fig.  3, E-H) and 
actin were characteristic of  epithelial cells and resembled the 
localization of E-cadherin and ZO-1  at the boundaries be- 
tween the cells. Following TGF-/3 treatment and fibroblast- 
like cell differentiation, the  immunoreactivity for desmo- 
plakin  disappeared  (Fig.  3  F),  and  the  vinculin  staining 
changed from a  peripheral pattern to a  punctate staining 
(Fig. 3 H). In epithelial cells, actin is connected with and 
becomes part of the zonula adherens and, accordingly, actin 
immunoreactivity  was detectable cortically in NMuMG cells 
before addition of TGF-/3. Following TGF-/3 tre~itment, actin 
was reorganized as longitudinal stress fibers in the spindle- 
shaped,  elongated cells,  characteristic of fibroblastic cells 
(Fig. 4, A and B). We also verified the subcellular localiza- 
tion of cytokeratin 18 (Fig. 4, C and D), which in untreated 
NMuMG cells has the characteristic epithelial staining pat- 
tern, but displays an altered distribution following TGF-/3 
treatment.  Finally,  the  immunofluorescence staining  pat- 
terns  of fibronectin and  vimentin expression were deter- 
mined.  Following TGF-/3 treatment,  the  staining  for both 
increased in intensity. Fibronectin was seen as a network sur- 
rounding the elongated cells (Fig. 4 F), while the vimentin 
filaments were organized as a longitudinal meshwork in the 
cells (Fig. 4 H). 
Western analysis was also performed to analyze the ex- 
pression levels of E-cadherin, fibronectin, vimentin and vin- 
culin  in  NMuMG  cells  before and  after TGF-/3-induced 
differentiation. In accordance with the immunohistochemi- 
cal staining, the expression level of E-cadherin decreased, 
whereas fibronectin expression increased (Fig. 5). The levels 
of vimentin and  vinculin expression remained  similar  in 
TGF-/%treated  and  -untreated  cells.  Thus,  the  TGF-/% 
induced changes in expression pattern of these two proteins 
visualized by immunofluorescence more likely reflect a reor- 
ganization of the cytoskeleton than an increase in expres- 
sion. To assess the expression level of the glycosylated frac- 
tion of E-cadherin,  which presumably correlates with the 
expression on the cell surface E-cadherin, Western blot anal- 
ysis was also done using cell lysates which were preabsorbed 
to concanavalin A.  Similar to the analyses of total cell ly- 
sates, TGF-fl treatment resulted in a decrease in the level of 
concanavalin A-bound E-cadherin (data not shown). Finally, 
analysis of the mRNA levels by Northern analysis showed a 
TGF-/%induced (2  ng/ml)  decrease in  E-cadherin mRNA 
and an increase in fibronectin mRNA (Fig. 6), in accordance 
with the corresponding protein levels. 
Miettinen et al. TGF-~ Induced Transdifferentiation  2025 Figure 3. Decreased expression of E-cadherin, ZO-I, desmoplakins 1 and 2 and vinculin after TGF-•  treatment of NMuMG cells. Cells 
were grown on coverslips in the absence (A, C, E, and G) or presence of TGF-/31 (B,/9, F, and H). After fixation and permeabilization, 
they were stained with antibodies to E-cadherin (A and B), ZO-1 (C and D), desmoplakins 1 and 2 (E and F) and vinculin (G and H). 
In untreated cells, all these cytoskeletal proteins were located cortically as a continuous line at the cell boundaries. However~ upon TGF- 
/~-induced phenotypic differentiation, E-cadherin and desmoplakins disappeared, ZO-1  immunoreactivity was decreased ~ind vinculin 
changed from a peripheral rim-like staining pattern to a punctate cytoplasmic one. Figure 4.  Localization  of actin, cytokeratin 18, fibronectin and vimentin in NMuMG ceils after TGF-B treatment.  Cells were grown on 
coverslips without (A, C, E, and G) or with TGF-B1 (B, D, F, and H). After fixation and permeabilization,  they were stained with antibodies 
to actin (A and B), cytokeratin 18 (C and D), fibronectin  (E and F) and vimentin  (G and H). In untreated cells, actin was localized cortically 
(A) but was reorganized into stress fibers during fibroblast-like differentiation (B). Cytokeratin 18 changed from a ring-like staining (C) 
to an irregular meshwork across the cells (D). Fibronectin  immunoreactivity  was strongly increased upon fibroblastic transition (F), while 
vimentin was mainly reorganized  to a network across the cells (H). Figure 5. Western analysis of 
NMuMG  cell  lysates  after 
TGF-/3 treatment.  NMuMG 
cells cultured without or with 
TGF-/31  (2  ng/ml  and  10 
ng/ml)  were  lysed,  and  the 
proteins  were  run  in  7.5% 
SDS-polyacrylamide  gel and 
electroblotted  to  nitrocellu- 
lose filters.  Western  analysis 
showed a decrease  in E-cad- 
herin expression  whereas fibro- 
nectin expression (arrow indi- 
cates  the  220-kD  band)  was 
increased.  There was no de- 
tectable change in vimentin or 
vinculin expression. 
Inhibition of TGF-{3-induced Differentiation  using 
Protein Kinase Inhibitors 
Because the type I  and type II TGF-/3 receptors are trans- 
membrane serine/threonine kinases, we evaluated the effect 
of several kinase inhibitors on the TGF-B-induced change in 
differentiation. Among these, we used (a) H7, which inhibits 
mainly protein kinase C and, at higher concentrations, pro- 
tein kinases A and G; (b) HA1004, a protein kinase A inhibi- 
tor; (c) staurosporin, a general protein kinase C  inhibitor; 
and (d) bisindolylmaleimide, caiphostin C and chelerythrine 
which are known to inhibit protein kinase C isoforms •,  B1, 
/~2, and 3'.  The inhibitors were added 5  rain before or af- 
ter the initiation of TGF-B treatment. H7 (50 ~M) and stau- 
rosporin (20 nM) were able to abolish or partially inhibit 
the  epithelial  to  fibroblastic  differentiation.  In  contrast, 
HA1004,  at concentrations (50 ~,M) that block protein ki- 
nase A  activity, had no effect suggesting that the inhibition 
seen with H7 may be mediated through an inhibition of a pro- 
tein kinase C. Most likely PKC-o~, -/3, or -7 are not involved, 
since  bisindolylmaleimide,  calphostin  C  or  ehelerythrine 
did not inhibit the transition in differentiation state. We then 
tested whether the phorbol ester TPA, an activator of protein 
kinase C, could induce the phenotypie differentiation by it- 
self. Our results showed that TPA alone was not able to in- 
duce the mesenchymal differentiation and that depletion of 
cellular PKC storage by long term (24 h) TPA pretreatment 
did not inhibit the TGF-/5-induced phenotypie change (data 
not shown). 
H7- and HA1004-treated NMuMG cells were also evalu- 
ated for their expression patterns of E-cadberin, fibronectin 
and ZO-1 using immunofluorescence (Fig. 7). Surprisingly, 
although H7 inhibited the TGF-/3-induced fibroblastic phe- 
notype, the decreased E-cadherin staining pattern was very 
Figure 6. Northern analysis of 
E-cadherin  and  fibronectin 
mRNA expression in NMuMG 
cells.  RNA  samples  (30 #g) 
from  untreated  (-/~)  and 
TGF-~l-treated  (+~;  2  ng/ 
ml)  cells  were  subjected  to 
Northern analysis. As shown, 
TGF-B  down-regulated E-cad- 
herin and increased fibronec- 
fin mRNA expression,  which 
correlate~ with  the  immuno- 
histochemical  results.  28S 
and  18S  were  stained  with 
methylene blue to verify equal 
RNA loading. 
similar to the TGF-B-treated cells in the absence of H7. Fur- 
thermore,  ZO-1  expression  in  TGF45-treated  cells  in  the 
presence of H7 also showed a pattern similar to the one in 
the absence of H7:ZO-1 was localized very coarsely and dot- 
like  at  the  cell-cell  boundaries  contrary  to  the  expected 
fine continuous tight-junctional expression in the untreated 
NMuMG epithelial cells. Finally, fibronectin immunoreac- 
tivity in the presence of H7 was increased after TGF-3 treat- 
ment, but it was detectable mainly in the cytoplasm instead 
of in the extracellular matrix outside the cells as seen in the 
absence of HT. 
Characterization  of Cells Expressing 
a Dominant-negative Form of the Tsk 7L 
I Receptor 
NMuMG cells make high levels of the TGF-/~/activin type 
I receptor Tsk7L and,  in fact, served as the mRNA source 
for the original Tsk7L eDNA cloning (Ebner et al.,  1993a). 
However, we were not able to detect mRNA levels for the 
type I receptor ALK-5/R-4/ESK-2 using either Northern hy- 
bridization or reverse transcriptase-PCR amplification (data 
not shown).  Thus,  we used NMuMG cells to evaluate the 
role of the Tsk 7L type I receptor in the TGF-/J-mediated ep- 
ithelial  to fibroblastic differentiation.  NMuMG cells were 
treated with antisense oligonucleotides for the TskTL type I 
and the type II receptor or with the corresponding sense oli- 
gonucleotides. Only the Tsk7L antisense oligonucleotides in- 
hibited the TGF-/3-induced fibroblastic phenotype, whereas 
the other oligonucleotides had no effect on the cell shape 
(data  not  shown).  Because  of the  possibility  that  some 
nonspecific effects may be associated with the exogenous use 
Figure 7. Effect of protein kinase inhibitors H7 and HA1004 on TGF-/~l-induced transdifferentiation.  Untreated NMuMG cells (,4, E, 
I, and M), cells treated with TGF-/3 (B, F, J, and At), 50 #M H7 plus TGF-/3 (C, G, K, and O), or 50/tM HA1004 plus TGF-/3 (D, H, 
L, and P) were grown on coverslips and stained with antibodies to E-cadherin (E-H), ZO-1 (I-L), and fibronectin (M-P). H7 inhibited 
the TGF-/~-induced transditferentiation (C), whereas HA1004 did not (/9). Although H7- plus TGF-B-treated cells looked epithelial, their 
E-cadherin  and ZO-1 expression was down-regulated and fibronectin expression was up-regulated.  Note that much of fibroneetin im- 
munoreactivity  is intracellularly  (P), instead of extracellular  localization as seen in cells treated with TGF-/3 only (At). 
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Tsk7L type I receptor. NMuMG cells were stably transfected with 
an expression vector for Tsk7L-DN lacking the cytoplasmic kinase 
domain. This truncated receptor also carries a carboxy-terminal 
FLAG epitope tag. (,4)  Transfected  clones selected for neomycin re- 
sistance were subjected to Northern analysis. As shown, wild type 
(WT) (lane 1 ) and stably transfected clones (lanes 2-5) all express 
the  full-length TskTL mRNA (upper  arrow),  while TskTL-DN 
mRNA expression is seen in three clones (lanes 2, 3, and 5, lower 
arrow). Among the Tsk7L-DN  transfected clones two high level ex- 
pressing clones (clones 1 and 2, lanes 2, 3), one low level express- 
ing clone (clone 6, lane 5) and one non-expressing clone (clone 5, 
lane 4) were chosen for further analyses. (B) Cell surface proteins 
from wild type  (WT, lane 3) and TskTL-DN-expressing clones 
(lanes 4-7) were biotinylated and immunoprecipitated with anti- 
FLAG antibody. The order of the different clones in lanes 4-7 is 
identical as  for lanes 2-5  in A.  As positive controls,  we used 
NMuMG cells transiently transfected with the Tsk7L-DN expres- 
sion plasmid using the Lipofactamine* (lane 1) or calcium phos- 
phate (lane 2) methods. All TskTL-DN  mRNA expressing clones 
expressed the 20-28-kD FLAG immunoreactive, truncated Tsk7L 
receptor at their cell surface. Their relative expression level of the 
truncated receptor correlated with the mRNA expression level. A 
similar 20-28-kD FLAG-immunoreactive  protein was precipitated 
from the transiently transfected NMuMG cells. Occasionally a faint 
band of  28 kD was seen in the wild-type cells (lane 3), but was con- 
sidered as nonspeeific. 
of antisense oligonucleotides, we wanted to confirm these 
results by overexpressing a cytoplasmically truncated form 
of the Tsk7L receptor. This mutant receptor lacks its cyto- 
plasmic kinase domain and most of the spacer domain that 
follows the transmembrane region and by analogy with the 
truncated type II receptor (Brand et al.,  1993; Chen et al., 
1993) is expected to exert a dominant negative inhibition on 
the signaling of the endogenous Tsk7L receptor. To allow 
specific  immunoprecipitation of the  truncated  Tsk7L-DN 
receptor, an eight-amino acid FLAG epitope tag was added 
to its C-terminal end. NMuMG cells were transfected with 
an expression plasmid for this truncated receptor and stable 
cell clones expressing TskTL-DN were established. The ex- 
pression levels of Tsk7L-DN in the stable clones were first 
analyzed by Northern analysis. Two clones expressing high 
levels of TskTL-DN mRNA and one expressing this mRNA 
at low level, as well as one negative control clone were cho- 
sen for further analyses (Fig. 8 A). To verify the expression 
of Tsk7L-DN at the cell surface, the cell surface proteins 
were biotinylated and subsequently immtmoprecipitated with 
an anti-FLAG antibody specific for Tsk7L-DN. The stable 
NMuMG clones expressing high levels of Tsk7L-DN mRNA 
showed a FLAG-immunoreactive band of 20--28 kD, which 
was also seen, albeit at lower levels, in the clone expressing 
a low level of Tsk7L-DN mRNA (Fig. 8 B). NMuMG cells 
transiently transfected with Tsk7L-DN were used as positive 
controls. They expressed a  FLAG-immunoreactive protein 
of the same size as the stable clones,  consistent with the 
predicted size of the FLAG-tagged truncated Tsk7L. As ex- 
pected, there is some heterogeneity in size because of the 
glycosylated nature of the receptor (data not shown).  Un- 
transfected NMuMG cells occasionally showed a band in the 
same  size range.  However, its  intensity was  considerably 
weaker and it was therefore considered nonspecific. 
The clones were also analyzed by immunohistochemical 
staining using the anti-FLAG monoclonal antibody. Clones 
expressing Tsk7L-DN mRNA and the corresponding FLAG- 
immunoreactive truncated receptor protein, also displayed a 
specific staining with anti-FLAG antibody at the cell surface, 
consistent with the membrane location of truncated Tsk7L. 
Untransfected NMuMG cells and neomycin-resistant control 
clones lacking Tsk7L-DN mRNA had a  weak background 
staining in the cytoplasm (data not shown). 
Cross-linking of the cell surface receptors using 'zSI-TGF-3 
showed only a  low level of ligand binding to the overex- 
pressed truncated Tsk7L receptor in the transfected clones 
(data not shown). This was expected since ligand binding to 
the type I receptors depends on the coexpression of the type 
II receptor (Ebner et al.,  1993a; Bassing et al.,  1994a; ten 
Dijke et al.,  1994) and the expression level of the type II re- 
ceptors is low in NMuMG cells (Ebner et al., 1993a). How- 
ever, transient coexpression of a transfected type II receptor 
in  these  Tsk7L-DN  clones  resulted  in  a  higher  level  of 
~25I-TGF-/~ cross-linking to the truncated Tsk7L type I  re- 
ceptor (data not shown), which is in agreement with the re- 
quired cooperativity for ligand binding. 
The transfected NMuMG clones expressing the truncated 
Tsk7L type I receptor were then tested for their phenotypic 
responsiveness to TGF-3. In contrast to the control clone and 
the parental untransfected NMuMG cells which underwent 
an epithelial to fibroblastic phenotypic change in response 
to TGF-/3, the clones expressing high levels of the truncated 
Tsk7L receptor did not alter their phenotype in response to 
TGF-3 or showed only a mild responsiveness (Fig. 9). The 
transfected clone expressing a low level of Tsk7L-DN mRNA 
and protein showed an intermediate phenotypic change in re- 
sponse to TGF-/3. 
The stable clones expressing the Tsk7L-DN receptor were 
also analyzed for the effect  of  TGF-3 treatment on several ep- 
ithelial/mesenchymal markers  using  immunofluorescence. 
Although the cell morphology did not become fibroblastic in 
these transfected cells, TGF-/~ affected the expression of sev- 
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sion of the Tsk7L-DN type I receptor on the 
TGF-/3-induced  epithelial to mesenchymal dif- 
ferentiation.  When stably transfected  Tsk7L-DN 
clones were treated with TGF-/~ (2 ng/ml) for 
36 h, no fibroblastic differentiation was seen 
in contrast to the parental NMuMG cells (see 
Fig. 1). 
eral marker proteins (Fig. 10). In the absence of TGF-/3, the 
expression patterns of  the markers in the T~kTL-DN express- 
ing clones were very similar to the untransfected cells. Fol- 
lowing TGF-/~ treatment,  E-cadherin immunoreactivity at 
the cell boundaries disappeared in the TskTL-DN transfected 
ceils, similarly to the change in the untransfected NMuMG 
cells (Fig.  10, A and B). Also, TGF-/~ induced a change in 
the localization of  ZO-1 protein in the TskTL-DN-transfected 
cells, which resembled the pattern in H7-treated, untrans- 
fected NMuMG cells in the presence of TGF-/~, i.e., ZO-1 
was  located in a  punctated fashion at the cell boundaries 
(Fig.  10, C and D) contrary to the fine, continuous staining 
seen in nontreated cells. Furthermore, actin was distributed 
both cortically and as stress fibers in TGF-/~-treated, Tsk7L- 
DN-expressing cells (Fig.  10, E  and F) and vinculin was 
present as intensely staining dots in the cell membrane of 
these cells (data not shown). The vinculin immunolocation 
was similar to TGF-/3-treated wild-type NMuMG ceils, al- 
though the intensity of the staining was more pronounced. 
Finally, immunoreactivity for fibronectin was increased in 
response to TGF-/~ and localized intracellularly (Fig.  10, G 
and H). Little fibronectin was detectable outside the cells in 
contrast to untransfected NMuMG cells. We also analyzed 
the  expression levels of E-cadherin and  fibronectin using 
Western analysis of cell lysates from untreated and TGF- 
/3-treated TskTL-DN clones. These results correlated with 
the immunohistochemical data, i.e., the level of E-cadherin 
was decreased and fibronectin expression was increased fol- 
lowing exposure of the Tsk7L-DN clones to TGF-/3. Also, 
Northern analyses showed that E-cadherin mRNA was de- 
creased and fibronectin mRNA was increased in these cells 
after TGF-/~ treatment (data not shown). 
Finally, we tested the effect of TGF-/3 on the proliferation 
rate of the transfected cells expressing the truncated Tsk7L 
type I receptor. [3H]thymidine incorporation was measured 
to assess  the inhibition of DNA synthesis by "rGF-/3. Our 
results  showed that  the  transfected clones  expressing  the 
truncated TskTL receptor were growth inhibited by TGF-/~, 
similar to the parental NMuMG cells (Fig.  11). The extent 
of TGF-/3-induced growth inhibition was somewhat higher 
in the high level Tsk7L-DN-expressing clones than in the un- 
transfected ceils. 
Discussion 
In this study, we show that mouse mammary epithelial cells 
undergo a reversible transition to a mesenchymal phenotype 
upon TGF-/3 treatment. Besides the change in cell morphol- 
ogy, this transition is characterized by downregulation of the 
expression of the epithelial markers E-cadherin, ZO-1,  and 
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differentiation  characteristics 
of Tsk7L-DN clones.  Stably 
transfected  clones  expressing 
Tsk7L-DN mRNA and protein 
(Fig.  8, A and B)  were ana- 
lyzed for their growth response 
to TGF-/3 treatment in serum- 
free  medium.  Their  rate  of 
DNA  synthesis  was  assayed 
by measuring uptake of [3H]- 
thymidine at 21 h after initia- 
tion  of TGF-/3 treatment.  In- 
dependent  of their  ability  to 
undergo  the  TGF-/3-induced 
epithelial-mesenchymal trans- 
differentiation,  all Tsk7L-DN 
clones were growth inhibited 
by TGF-3. 
desmoplakins I and II. In addition, there is an increased ex- 
pression of the mesenchymal marker fibronectin and a reor- 
ganization of actin stress fibers and vimentin from an epithe- 
lial to a  fibroblastic pattern.  Since the  cellular phenotype 
before and after TGF-3 treatment is clearly distinguishable 
and the resulting fibroblast-like cells originate from the epi- 
thelial  cells,  we  conclude  that  this  TGF-/3-induced  pro- 
cess fulfills the criteria of transdifferentiation (Eguchi and 
Kodama, 1993). An elongation of human mammary epithe- 
lial cells in the presence of TGF-3 has previously been no- 
riced, but no further characterization was carried out (Hoso- 
buchi  and  Stampfer,  1989).  Several  other  growth  factors 
have earlier been shown to induce an epithelial to fibroblas- 
tic differentiation. TGF-o~ and acidic FGF induce a fibroblas- 
tic differentiation of bladder epithelial carcinoma cells,  as 
based on their change in morphology and the differential ex- 
pression of several of the same markers as used in our cur- 
rent study (Gavrilovic et al.,  1990; Valles et al.,  1990). Fur- 
thermore,  overexpression  of  scatter  factor/HGF  and  its 
tyrosine kinase receptor, c-met, is able to induce a transition 
from fibroblastic to  an epithelial  phenotype in  3T3  fibro- 
blast-derived tumor cells (Tsarfaty et al.,  1994).  All these 
factors are mitogenic growth factors and mediate their effects 
following binding to transmembrane tyrosine kinase recep- 
tors,  in  contrast to  TGF-/3,  which  signals  through  serine/ 
threonine kinase receptors and is growth inhibitory. The cur- 
rent demonstration that TGF-3 induces an epithelial to mes- 
enchymal transdifferentiation  is  not  only restricted  to the 
mammary epithelial cell line tested, but was also apparent 
in other epithelial cell lines. 
Several epithelial cell types can be induced to transform 
to mesenchymal cells by extracellular  matrix e.g.,  retinal 
pigmented epithelial cells (Eguchi and Okada, 1973; Green- 
burg and Hay, 1986), notochordal epithelial cells and thyroid 
epithelial  cells  (Greenburg  and  Hay,  1988).  Epithelial  to 
mesenchymal conversion of defined  cell  types  also  takes 
place during  development.  As an example, embryonic ec- 
todermal  cells  of the  posterior  epiblast  differentiate  into 
mesenchymal cells which subsequently migrate away from 
their original site (Burdsal et al.,  1993).  How such transi- 
tions are induced in vivo is as yet unclear, but it is conceiv- 
able that localized extracellular matrix proteins and growth 
factors are involved. Our current findings emphasize the pos- 
sibility that TGF-3 may be involved in epithelial to mesen- 
chymal transdifferentiation  during  development and organ 
morphogenesis. In addition, TGF-/~ is capable to transdiffer- 
entiate endothelial cells of atrioventricular canal (Potts and 
Runyan, 1989) and fat-storing ceils of liver to mesenchymal- 
like cells (Bachem et al.,  1993). The ability of TGF-/3 to in- 
duce  mesenchymal  differentiation  of epithelial  cells  may 
have a considerable importance during development and or- 
gan morphogenesis. Specifically, with respect to mammary 
epithelial  cells,  TGF-/3  has  the  ability  to  inhibit  ductal 
branching  morphogenesis  (Silberstein  and  Daniel,  1987). 
Figure 10.  Effect of TGF-/3 treatment on E-cadherin,  ZO-1, actin and fibronectin expression in Tsk7L-DN clones. Cells were grown on 
coverslips without (A, C, E, and G) or with TGF-/31 (B, D, F, and H). After fixation and permeabilization, they were stained with antibodies 
to E-cadherin (A and B), ZO-I (C and D), actin (E and F), and fibronectin (G and H). In the absence of TGF-/3, E-cadherin,  ZO-1, and 
actin were located conically as a continuous line, similar to wild-type NMuMG cells (Figs. 3 and 4). However, TGF-/3 treatment resulted 
in a disappearance of E-cadherin immunoreactivity  (B) and a decreased ZO-1 staining (D), even though the cell morphology remained 
epithelial. Also, actin was again reorganized into stress fibers resembling fibroblasts (F). Fibronectin expression was increased in the pres- 
ence of TGF-3, but was mainly localized intracellularly  instead of extracellnlarly  (H). 
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directed overexpression of active TGF-B1 in the mammary 
gland inhibited duct formation (Pierce et al.,  1993). The in- 
hibition  of branching  morphogenesis  by  "lX3F-j3 together 
with its ability to regulate extracellular matrix deposition 
and the currently described activity as a reversible inducer 
of epithelial  to  mesenchymal  transdifferentiation imply  a 
complex role for TGF-B as a physiological regulator of mam- 
mary gland function. 
The mechanistic basis for the TGF-~-induced epithelial to 
mesenchymal transdifferentiation of NMuMG  cells is un- 
clear. Considering the postulated role of E-cadherin in the 
maintenance of the epithelial phenotype (Nagafuchi et al., 
1987; Matsuzaki et al.,  1990), it is conceivable that down- 
regulation  of its  expression  and  localization  at  the  cell 
boundaries may play an important role in the transdifferenti- 
ation phenomenon both during development and carcinogen- 
esis. This possibility is substantiated by the observation that 
neutralizing anti-E-cadherin antibodies induce a change in 
epiblast cells from an epithelial to mesenchymal morphol- 
ogy, strongly suggesting that disruption of E-cadherin func- 
tion results in their acquisition of phenotypic characteristics 
of mesoderm (Burdsal et al.,  1993).  Furthermore, loss of 
E-cadherin expression can also lead to dedifferentiation and 
invasiveness  of  carcinoma  cells,  and  overexpression  of 
E-cadherin in poorly differentiated carcinoma cell lines in- 
hibits invasiveness (Behrens et al., 1989; Frixen et al., 1991; 
Sommers et al.,  1992). However, the decreased E-cadherin 
expression in the TGF-B-treated NMuMG cells may not be 
the driving factor that induces complete transdifferentiation 
since the TGF-j3-treated, Tsk7L-DN-expressing NMuMG 
cells look epithelial, yet have decreased E-cadherin expres- 
sion. Finally, our results also illustrate the ability of TGF-/3 
to inhibit E-cadherin expression. No growth and differentia- 
tion  factors  have  previously  been  shown  to  modulate 
E-cadherin expression. Thus, TGF-j3 may play a role in the 
regulation of E-cadherin synthesis in vivo and could thus 
have  a  functional  significance  for  the  downregulation  of 
E-cadherin  expression  during  normal  and  tumor  devel- 
opment. 
Little is known about the TGF-~ receptor-mediated signal- 
ing  events  following  ligand  binding  (Derynck,  1994b). 
TGF-~ mediates its activities through the type I and II recep- 
tors,  which  are  both  transmembrane  serine/threonine ki- 
nases. At least several of the TGF-B responses, e.g., induc- 
tion  of  c-jun,  fibronectin,  and  plasminogen  activator 
inhibitor 1 as well as the antiproliferative effect of TGF-~, 
are inhibited by the protein kinase inhibitor H7 (Ohtsuki and 
Massagu6,  1992).  We now show that the TGF-B-induced 
transdifferentiation of NMuMG cells can be inhibited by H7 
and staurosporine, but not by HA1004,  suggesting an in- 
volvement of a protein kinase C.  This would be consistent 
with the observed translocation of protein kinase C to the 
cell  membrane  in  astrocytes  in  the  presence  of  TGF-~ 
(Robertson et al., 1988).  However, bisindolylmaleimide and 
calphostin  C,  which  inhibit  the  protein  kinase  isoforms 
PKC-a, -flI, -~II, and -3', failed to inhibit transdifferentia- 
tion, and the phorbol ester TPA, which activates several PKC 
isoforms, did not induce transdifferentiation. This suggests 
that other PKC isoforms, such as the TPA-resistant PKC-~" 
or -~ might be involved or that, even though required, activa- 
tion of PKC alone is not sufficient for the induction of trans- 
differentiation. The increased intracellular immunoreactiv- 
ity for fibronectin in H7-treated cells and in the Tsk7L-DN 
clones  following  TGF-~  treatment  is  in  agreement  with 
previous findings showing that fibronectin matrix assembly 
is  modulated by  PKC-mediated phosphorylation (Somers 
and Mosher, 1993). Thus, TGF-t3-mediated signaling could 
directly modulate the cytoskeletal organization. It is obvi- 
ously also possible that the inhibitors we have used directly 
block the kinase activities of the type I  or type II TGF-/3 
receptors. However, this is unlikely since in vitro kinase as- 
says indicate that Tsk7L type I receptor and type II receptor 
autophosphorylation are not inhibited by H7 (Lawler, S., 
R.  M.  Maruoka,  and  R.  Derynck,  unpublished  results). 
Taken together, our results using protein kinase inhibitors in- 
dicate the involvement of at least one kinase activity down- 
stream from the TGF-B receptors and raise the possibility of 
an involvement of a protein kinase C in the TGF-/3-signaling 
pathway. 
As shown in this report, NMuMG cells undergo an epithe- 
lial to mesenchymal transdifferentiation upon exposure to 
"IX3F-B, but not activin. Because these cells express a high 
level of Tsk7L type I receptors, but not ALK-5/R4/ESK-2, 
we evaluated the role of Tsk7L in the transdifferentiation. 
Using antisense oligonucleotides specific for Tsk7L and by 
overexpressing a  truncated kinase-negative form of Tsk7L 
that functions as a dominant negative mutant, we were able 
to abolish this TGF-B-mediated change in cell morphology. 
These results strongly suggest that the type I receptor Tsk7L 
may be important for the transdifferentiation process. By far 
the  most  likely explanation  is  that  Tsk7L  functions  as  a 
TGF-~ receptor that mediates this  response,  a possibility 
reinforced by the binding of TGF-~ to both the full-size and 
truncated Tsk7L (Ebner et al.,  1993a,b; data not shown). It 
cannot, however, be formally excluded that TGF-~ induces 
the synthesis of another TGF-~-related factor which exerts 
its transdifferentiating activity through Tsk7L. 
Although  the  Tsk7L-DN stable  clones did not undergo 
fibroblastic transdifferentiation, they were still growth in- 
hibited by TGF-~ and showed an increased fibronectin syn- 
thesis and decreased E-cadherin and ZO-1 immunostaining 
when exposed to TGF-~. This difference in inhibition of the 
responses can as yet not be fully explained based on the cur- 
rent limited data on receptor activation, especially consider- 
ing the multiplicity of type I receptors. The type II receptor 
has clearly been demonstrated necessary for the antiprolifer- 
ative effect of TGF-~ in epithelial cells (Chen et al.,  1993), 
and is thought to cooperate with a kinase-active type I recep- 
tor for this activity (Wieser et al.,  1993). However, the fact 
that growth inhibition and upregulation of fibronectin syn- 
thesis by TGF-~ are maintained in the Tsk7L-DN clones, 
would argue that either functional Tsk7L receptors are not 
required for these activities or that another type I receptor 
mediates these responses to TGF-/~. Other type I receptors, 
such as TSR-1, that can bind TGF-fl in the presence of the 
type II  receptor could be  involved in  these responses  in 
NMuMG cells. Furthermore, TGF-~-mediated gene activa- 
tion in NMuMG cells could also happen independently of 
growth inhibition as shown in other cell lines (Zentella et al., 
1991; Geiser et al.,  1992;  Fafeur et al.,  1993;  Stampfer et 
al.,  1993).  Alternatively, the dominant negative inhibition 
may  not  be  complete allowing  a  residual  level of Tsk7L 
receptor function, or the truncated Tsk7L could nonspecifi- 
The Journal  of Cell Biology, Volume 127, 1994  2034 cally inhibit an otherwise functional receptor complex. How- 
ever, the fact that Tsk7L-DN selectively abolishes only one 
of the TGF-/3-mediated pathways,  i.e., the transdifferentia- 
tion, argues against these possibilities. Obviously, extensive 
characterization of the signaling activities  and the physio- 
logical  interactions  between  the  type  II  and the  different 
type I receptors will be required  before we will be able to 
understand  how the TGF-/3 responsiveness and the diversity 
of activities induced by TGF-/3 is determined for a particular 
cell line and cell type. Nonetheless, our data support a role 
for the Tsk7L type I receptor in the TGF-/%mediated  trans- 
differentiation  of mammary epithelial cells. 
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